Changes in body composition in early breast cancer patients treated with aromatase inhibitors.

IF 5.4 2区医学 Q1 Medicine

Journal of Endocrinological Investigation Pub Date : 2024-06-10 DOI:10.1007/s40618-024-02401-7

R Pedersini, G Schivardi, L Laini, M Zamparini, A Bonalumi, P di Mauro, S Bosio, V Amoroso, N Villa, A Alberti, N Di Meo, C Gonano, B Zanini, M Laganà, G Ippolito, L Rinaudo, D Farina, M Castellano, C Cappelli, E L Simoncini, D Cosentini, A Berruti

{"title":"Changes in body composition in early breast cancer patients treated with aromatase inhibitors.","authors":"R Pedersini, G Schivardi, L Laini, M Zamparini, A Bonalumi, P di Mauro, S Bosio, V Amoroso, N Villa, A Alberti, N Di Meo, C Gonano, B Zanini, M Laganà, G Ippolito, L Rinaudo, D Farina, M Castellano, C Cappelli, E L Simoncini, D Cosentini, A Berruti","doi":"10.1007/s40618-024-02401-7","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of the study was to analyze the modification of total and regional body composition in early breast cancer patients treated with aromatase inhibitors (AIs).Methods: This is a prospective, single-center, observational, longitudinal study. Four-hundred and twenty-eight patients treated with adjuvant aromatase inhibitors were enrolled at the Medical Oncology and Breast Unit of Spedali Civili Hospital in Brescia from September 2014 to June 2022. Several body composition parameters including total and regional fat and lean body mass were investigated with dual-energy X-ray absorptiometry (DXA) scan at baseline and after 18 months of treatment with aromatase inhibitors.Results: A significant increase in fat body mass (mean + 7.2%, 95% confidence interval [CI]: 5.5;8.9%) and a reduction in lean body mass (mean -3.1%, 95% CI -3.9; -2.4) were documented in this population. The changes in fat and lean body mass varied considerably according to different body districts ranging between + 3.2% to + 10.9% and from-1.3% to -3.9%, respectively.Conclusion: Aromatase inhibitor adjuvant therapy in early breast cancer is associated with changes in body composition, with a wide variability among different body districts, leading to a risk of sarcopenic obesity. Supervised physical exercise that focuses on single body parts that may display detrimental variations may be beneficial for AIs treated patients.","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endocrinological Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40618-024-02401-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim of the study was to analyze the modification of total and regional body composition in early breast cancer patients treated with aromatase inhibitors (AIs).

Methods: This is a prospective, single-center, observational, longitudinal study. Four-hundred and twenty-eight patients treated with adjuvant aromatase inhibitors were enrolled at the Medical Oncology and Breast Unit of Spedali Civili Hospital in Brescia from September 2014 to June 2022. Several body composition parameters including total and regional fat and lean body mass were investigated with dual-energy X-ray absorptiometry (DXA) scan at baseline and after 18 months of treatment with aromatase inhibitors.

Results: A significant increase in fat body mass (mean + 7.2%, 95% confidence interval [CI]: 5.5;8.9%) and a reduction in lean body mass (mean -3.1%, 95% CI -3.9; -2.4) were documented in this population. The changes in fat and lean body mass varied considerably according to different body districts ranging between + 3.2% to + 10.9% and from-1.3% to -3.9%, respectively.

Conclusion: Aromatase inhibitor adjuvant therapy in early breast cancer is associated with changes in body composition, with a wide variability among different body districts, leading to a risk of sarcopenic obesity. Supervised physical exercise that focuses on single body parts that may display detrimental variations may be beneficial for AIs treated patients.

Abstract Image

查看原文本刊更多论文

接受芳香化酶抑制剂治疗的早期乳腺癌患者身体成分的变化。

目的：本研究旨在分析接受芳香化酶抑制剂（AIs）治疗的早期乳腺癌患者的总体和区域身体成分变化情况：这是一项前瞻性、单中心、观察性纵向研究。2014年9月至2022年6月期间，布雷西亚Spedali Civili医院肿瘤内科和乳腺科招募了428名接受芳香化酶抑制剂辅助治疗的患者。在使用芳香化酶抑制剂进行治疗的基线和18个月后，通过双能X射线吸收测量（DXA）扫描对包括总脂肪量、区域脂肪量和瘦体重在内的多项身体成分参数进行了调查：结果：该人群的脂肪体质量明显增加（平均 + 7.2%，95% 置信区间 [CI]：5.5; 8.9%），瘦体重减少（平均 -3.1%，95% 置信区间 -3.9; -2.4）。不同身体部位的脂肪和瘦体重的变化差异很大，分别为 + 3.2% 至 + 10.9% 和 - 1.3% 至 -3.9%：结论：芳香化酶抑制剂对早期乳腺癌的辅助治疗与身体成分的变化有关，不同体质区之间的差异很大，可能导致肌肉疏松性肥胖。针对可能出现不利变化的单个身体部位进行有指导的体育锻炼，可能对接受 AIs 治疗的患者有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Endocrinological Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

8.10

自引率

7.40%

发文量

242

期刊介绍： The Journal of Endocrinological Investigation is a well-established, e-only endocrine journal founded 36 years ago in 1978. It is the official journal of the Italian Society of Endocrinology (SIE), established in 1964. Other Italian societies in the endocrinology and metabolism field are affiliated to the journal: Italian Society of Andrology and Sexual Medicine, Italian Society of Obesity, Italian Society of Pediatric Endocrinology and Diabetology, Clinical Endocrinologists’ Association, Thyroid Association, Endocrine Surgical Units Association, Italian Society of Pharmacology.

文献相关原料

公司名称	产品信息	采购帮参考价格